STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 March 2004 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
• 
On  12  May  1997,  the  Marketing  Authorisation  Holder  (MAH)  notified  the  EMEA  in 
accordance  with  Article  10(3)  Council  Directive  92/27/EEC  of  their  intention  to  introduce  a 
change  to  an  aspect  of  the  Package  Leaflet  (PL)  not  connected  with  the  Summary  of  Product 
Characteristics  (SPC).  The  scope  of  the  variation  concerned  minor  amendments  to  the  PL  for 
clarification and consistency with the SPC together with translation corrections. The procedure 
started  on  the  24  October  1997  and  the  EMEA  notified  the  European  Commission  on  13 
January 1998 that these changes were accepted. 
On 12 September 1997, the MAH submitted an application for a type II variation in accordance 
with Commission Regulation (EC) No 542/95. The scope of the variation concerned an update 
of  the  safety  section  of  the  SPC  as  a  result  of  recommendations  from  the  CPMP  following 
assessment of the 1st PSUR and a clinical pharmacokinetics report in subjects with cirrhosis. On 
19  November  1997  the  CPMP  adopted  a  positive  opinion  on  the  type  II  variation.  The 
respective Commission Decision was issued on 26 March 1998.  
On  31  October  1997  the  MAH  submitted  three  parallel  applications  for  type  I  variations  in 
accordance with Commission regulation (EC) No 542/95. The MAH applied for a change in the 
name  of  one  of  the  manufacturing  sites,  the  address  for  a  contract  packaging  site  and  a 
correction of an error in the specification of the first intermediate in the synthesis of the active 
substance  olanzapine.  The  procedure  started  on  24  November  1997.  The  EMEA  notified  the 
European Commission on 18 December 1997 that the above variations were accepted. 
On 8 April 1998, the MAH submitted an application for a type II variation in accordance with 
Article 6 of Commission Regulation (EC) No 542/95. The scope of the variation concerned an 
update  of  the  safety  sections  of  the  SPC  and  PL  as  a  result  of  CPMP  recommendations 
following  the  assessment  of  the  2nd  PSUR  and  a  review  of  available  spontaneous  reports  for 
seizures in association with olanzapine. On 25 June 1998 the CPMP adopted a positive opinion 
issued  on  
on 
22 October 1998. 
respective  Commission  Decision  was 
II  variation.  The 
type 
the 
On  29  July  1998,  the  MAH  submitted  two  parallel  applications  for  type  I  variations  in 
accordance with Article 4 of Commission Regulation (EC) No 542/95. The MAH applied for an 
extension  of  retest  period  of  the  active  substance  from  18  to  36  months  and  an  extension  of 
shelf  life  from  two  to  three  years.  The  procedure  started  on  8  September  1998.  The  EMEA 
notified  the  European  Commission  that  the  variations  were  accepted  on  1  October  and  3 
November  1998,  respectively.  The  respective  Commission  Decision  was  issued  on  17 
December 1998. 
On 21 December 1998, the MAH submitted an application for a type I variation in accordance 
with Article 4 of Commission Regulation (EC) No 542/95. The MAH applied for an increase in 
the batch size of the finished product. The procedure started on 23 December 1998. The EMEA 
notified the European Commission on 17 February 1999 that the above mentioned variation was 
accepted. 
On 29 December 1998, the MAH submitted an application for a type II variation in accordance 
with Article 6 of Commission Regulation (EC) No 542/95. The MAH applied for an update of 
the safety sections of the SPC as a result of CPMP recommendations following the assessment 
of the 3rd PSUR. In accordance with the suggestions in the Rapporteur's assessment report on a 
previous  type  II  variation,  the  MAH  proposed  to  include  a  description  on  interactions  with 
fluoxetine into the SPC. On 21 April 1999 the CPMP adopted a positive opinion on the type II 
variation. The respective Commission Decision was issued on 19 July 1999. 
On  4  May  1999,  the  MAH  submitted  an  application  for  a  type  I  variation  in  accordance  with 
Article 4 of Commission Regulation (EC) No 542/95. The MAH applied for an increase in the 
batch  size  of  the  active  substance  olanzapine.  The  procedure  started  on  11  May  1999.  The 
1/5 
EMEA 2005 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
EMEA notified the European Commission on 9 June 1999 that the variation was accepted and 
did not require any amendment to the Community Marketing Authorisation. 
On  1  July  1999,  the  MAH  submitted  an  application  for  a  type  I  variation  in  accordance  with 
Article 4 of Commission Regulation (EC) No 542/95. The MAH applied for an increase in the 
batch size of the finished  product. The procedure started on 6 July 1999. The EMEA notified 
the European Commission on 21 July 1999 that the variation was accepted. And did not require 
any amendment to the Community Marketing Authorisation. 
On 24 August 1999, the MAH submitted an application for a type I variation in accordance with 
Article  4  of  Commission  Regulation  (EC)  No  542/95.  The  MAH  applied  to  delete  one  of  the 
authorised assembly sites. The procedure started on 2 September 1999. The EMEA notified the 
European  Commission  on  24  September  1999  that  the  variation  was  accepted  and  did  not 
require any amendment to the Community Marketing Authorisation. 
On  9  December  1999,  the  MAH  submitted  to  the  EMEA  a  line-extension  application  for  the 
Marketing  Authorisation  for  Zyprexa  15  and  20  mg  coated  tablets,  under  Annex  II  to 
Commission Regulation (EC) No. 542/95. On 21 September 2000 the CPMP adopted a positive 
opinion on the application. The respective Commission Decision to authorise the 15 and 20 mg 
strengths was issued on 27 December 2000. 
On 20 December 1999, the MAH submitted to the EMEA an application for a type II variation 
in accordance with Article 6 of Commission Regulation (EC) No 542/95 of 10 March 1995, as 
amended. The scope of the variation was to update the section 4.5 and 4.8 of the SPC to include 
potent  inhibitors  of  P450-1A2  activity,  bradycardia  and  abnormal  gait  in  patients  with 
Alzheimer’s disease following the 5th PSUR. Some minor typographical corrections in the SPC 
and  PL  were  also  applied  for.  On  25  May  2000  the  CPMP  adopted  a  positive  opinion..  The 
respective Commission Decision was issued on 25 September 2000. 
On  7  March  2000,  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of this variation was for a minor change in the manufacturing process of the active substance. 
The procedure started on 13 March 2000. The EMEA notified the European Commission on 10 
April  2000  that  the  variation  was  accepted  and  did  not  require  any  amendment  to  the 
Community  Marketing  Authorisation.  Pursuant  to  Article  4  of  Commission  Regulation  (EC) 
No. 542/95 of 10 March 1995 as amended, the MAH submitted to the EMEA on 4 April 2000 
an  application  for  a  type  I  variation  for  Zyprexa.  The  scope  of  the  variation  was  to  add  a 
contract packaging facility. The EMEA notified the European Commission on 4 May 2000 that 
the  variation  was  accepted  and  did  not  require  any  amendment  to  the  Community  Marketing 
Authorisation. 
On  8  May  2000,  the  MAH  submitted  to  the  EMEA  a  line-extension  application  for  the 
Marketing Authorisation for Zyprexa 10 mg Powder for Solution for Injection and Powder and 
Solvent for Solution for Injection, under Annex II to Commission Regulation (EC) No. 542/95. 
The procedure started on 23 May 2000. The Rapporteur’s assessment report  was circulated to 
CPMP  members  on  31  July  2000  and  the  final  consolidated  list  of  questions  was  sent  to  the 
MAH on 22 September 2000. The MAH submitted the responses to the CPMP consolidated list 
of questions on 21 November 2000. On 29 March 2001 the CPMP adopted a positive opinion 
on  the  application.  The  respective  Commission  Decision  to  authorise  the  Zyprexa  10  mg 
Powder for Solution for Injection and Powder and Solvent for Solution for Injection was issued 
on 2 July 2001. 
On  10  May  2000,  the  MAH  submitted  an  application  for  a  typ  I  varation  in  accordance  with 
Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995 as amended. The scope 
of the variation was to to introduce an additional pack size being a blister pack of 28 tablets for 
Zyprexa 7.5 mg coated tablets. The EMEA notified the European Commission on 15 May 2000 
that  the  variation  was  accepted.  The  respective  Commission  Decision  was  issued  on  10  July 
2000. 
On 21 June 2000, the MAH submitted an application for a type II variation in accordance with 
Article 6 of Commission Regulation (EC) 542/95 as amended. The scope of the variation was to 
2/5 
EMEA 2005 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
update  the  SPC  and  PL  based  on  the  5th  PSUR.  The  procedure  started  on  30  June  2000.  The 
CPMP  adopted  a  positive  Opinion  for  this  variation  on  21  September  2000.  The  respective 
Commission Decision was issued on 27 December 2000.  
On 6 December 2000, the MAH submitted an application for a type II variation in accordance 
with Article 6 of Commission Regulation (EC) 542/95 as amended. The scope of the variation 
was to update of the section 4.8 of the SPC regarding information on hyperglycaemia, and the 
respective section of the PL to reflect this change. The procedure started on 15 December 2000. 
The  CPMP  adopted  a  positive  Opinion  for  this  variation  on  1  March  2001.  The  respective 
Commission Decision was issued on 14 June 2001.  
On 13 December 2000, the MAH submitted an application for a type I variation in accordance 
with Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995 as amended. The 
scope  of the  variation  was to  add alternative ink for  the  imprinting of the tablets. The EMEA 
notified the European Commission on 13 February 2001 that the variation was accepted and did 
not require any amendment to the Community Marketing Authorisation.. 
On 11 January 2001, the MAH submitted to the EMEA an application for a type I variation in 
accordance  with  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended.  The  scope  of  the  variation  was  to  add  additional  batch  sizes  for  5  mg  and  10  mg 
tablets. The EMEA notified the European Commission on 20 February 2001 that the variation 
was accepted and did not require any amendment to the Community Marketing Authorisation. 
On 19 February 2001, the MAH submitted to the EMEA an application for a type I variation in 
accordance with Article 4 of European Commission Regulation (EC) No. 542/95, as amended. 
The scope of the variation was to change the address of the MAH. The procedure started on 23 
February  2001.  The  EMEA  notified  the  European  Commission  on  1  March  2001  that  the 
variation  was  accepted.  Amendments  to  the  Annexes  I,  IIIA  and  IIIB  were  required  and  the 
Commission Decision was issued on 14 June 2001. On 14 March 2001, the MAH submitted an 
application for a type II variation in accordance with Article 6 of Commission Regulation (EC) 
542/95 as amended. The MAH applied for an extension of the therapeutic indication to patients 
with bipolar disorder suffering from a manic episode. The CPMP adopted a positive Opinion for 
the indication “olanzapine is indicated for the treatment of a moderate to severe manic episode; 
olanzapine  has  not  been  demonstrated to prevent recurrence of  manic  or  depressive episodes” 
on 21 February 2002. The respective Commission Decision was issued on 4 June 2002. 
On  23  July  2001,  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope of this variation was to add an alternative packaging and release site. The EMEA notified 
the  European  Commission  on  24  August  2001  that  the  variation  was  accepted.    The  respective 
Commission Decision was issued on 19 October 2001. 
For  the  first  renewal  of  Zyprexa,  the  CPMP  was  of  the  opinion  that  the  quality,  safety  and 
efficacy of this medicinal product continued to be adequately and sufficiently demonstrated and 
therefore  considered  that  the  benefit/risk  profile  continued  to  be  favourable  for  the  authorised 
indications  and  issued  on  26  July  2001  a  positive  opinion  for  the  renewal  of  Community 
Marketing Authorisation. The respective Commission Decision of the renewal was issued on 20 
November 2001. 
On 14 December 2001, the MAH submitted to the EMEA an application for a type I variation in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope of this variation was a minor change to the coating weight of tablets. This variation was 
approved by the EMEA on 29 January 2002. The variation did not require any amendment to 
the Community Marketing Authorisation. 
On 12 February 2002, the MAH submitted an application for a type II variation in accordance 
with Article 6 of Commission Regulation (EC) 542/95 as amended. The procedure started on 22 
February  2002.  The  MAH  applied  for  an  update  of  the  SPC  sections  4.8  and  4.5  and  the 
corresponding sections of the PL following the 7th PSUR. The procedure started on 22 February 
2002.  The  CPMP  adopted  a  positive  Opinion  on  30  May  2002.  The  respective  Commission 
Decision was issued on 9 September 2002. 
3/5 
EMEA 2005 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
On 18 March 2002, the MAH submitted to the EMEA an application for a type I variation in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope  of  this  variation  was  to  add  a  new  packaging  site  and  rename  an  authorised  packaging 
site.  This  variation  was  accepted  by  the  EMEA  on  15  April  2002  and  did  not  require  any 
amendment to the Community Marketing Authorisation. 
On 18 May 2002, the MAH submitted an application for a type II variation in accordance with 
Article  6  of  European Commission  Regulation (EC) 542/95 as  amended. The procedure  started 
on  31  May  2002.  The  MAH  applied  for  an  update  of  the  section  4.1  of  the  SPC  to  extend  the 
therapeutic  indication  of  Zyprexa  Powder  and  Solvent  for  Solution  for  Injection  to  agitated 
patients  with  manic  episode.  The  CPMP  adopted  a  positive  Opinion  on  25  July  2002.  The 
respective Commission Decision was issued on 18 October 2002. 
Pursuant to article 61(3) of Council Directive No. 2001/83/EC of 6 November 2001, the MAH 
notified the EMEA on 15 October 2002 of their intention to introduce changes to an aspect of 
the  PL  not  connected  to  the  SPC.  On  25  October  2002,  the  EMEA  notified  the  European 
Commission  that  the  changes  were  accepted  and  did  not  require  any  amendment  to  the 
Community Marketing Authorisation.  
On  6  December  2002,  the  MAH  submitted  an  application  for  a  type  II  variation  in  accordance 
with Article 6 of Commission Regulation (EC) 542/95 as amended. The procedure started on 20 
December  2002.  The  application  related  to  an  update  in  section  4.1  of  the  SPC  to  extend  the 
therapeutic indication to include prevention of recurrence in  patients with bipolar disorder.  The 
CPMP adopted a positive Opinion on 27 July 2003 for the indication “olanzapine is indicated for 
the  prevention  of  recurrence  in  patients  with  bipolar  disorder”.  The  respective  Commission 
Decision was issued on 24 October 2003. 
On 4 February 2003, the MAH submitted an application for a type II variation in accordance with 
Article  6  of  Commission  Regulation  (EC)  542/95  as  amended.  The  procedure  started  on  24 
February  2003.  The  application  referred  to  an  update  to  section  4.6  of  the  SPC  regarding  the 
levels  of  olanzapine  found  in  breast  milk,  as  well  as  section  4.8  regarding  EPS  following  the 
review of the 9th PSUR. The CPMP adopted a positive Opinion on 26 June 2003. The respective 
Commission Decision was issued on 8 October 2003. 
On  5  March  2003,  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope  of  this  variation  was  to  change  the  qualitative  composition  of  the  immediate  packaging 
material.  This  variation  was  accepted  by  the  EMEA  on  7  April  2003  and  did  not  require  any 
amendment to the Community Marketing Authorisation. 
On 5 September 2004, the MAH submitted to the EMEA an application for a type I variation in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope of the variation was to add a new manufacturing site for part or all of the manufacturing 
process. The variation was accepted by the EMEA on 2 October 2003. 
On  5  February  2004,  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope of the variation was to add an additional manufacturing site and as a consequence increase 
the batch size. The variation was accepted by the EMEA on 2 October 2003. 
On 12 February 2004, the MAH submitted to the EMEA an application for a type I variationper 
Annex  I  (No.  IA41a01)  of  Commission  Regulation  EC)  No.  1085/2003.  The  scope  of  the 
variation was to add a new pack size containing 56 coated tablets packed in blister strips for the 
2.5 mg, 5.0 mg, 15 mg and 20 mg strengths of Zyprexa coated tablets. The variation was accepted 
by the EMEA on 26 February 2004. 
On 11 February 2004, the MAH submitted to the EMEA an application for a type I variation as 
per  Annex I  (No  IA47a) in accordance with  Commission  Regulation (EC)  No.  1085/2003.  The 
scope of this variation was to delete the bottle presentation for the 2.5 mg, 5 mg, 7.5 mg, 10 mg, 
15 mg and 20 mg strengths of Zyprexa coated tablets. This variation was accepted by the EMEA 
on 7 April 2003. 
4/5 
EMEA 2005 
 
 
 
 
 
• 
• 
On 20 February 2004, the MAH submitted to the EMEA an application for a type I variation as 
per  Annex  I  (No  IA08a)  of  Commission  Regulation  (EC)  No.  1085/2003.  The  scope  of  this 
variation was to add an additional facility for the control testing of Zyprexa coated tablets. This 
variation was accepted by the EMEA on 27 February 2004. 
On  1  March  2004,  an  Urgent  Safety  Restriction  procedure  was  started  at  the  request  of  the 
MAH  to  include  information  on  cerebrovascular  adverse  events  and  increased  mortality  in 
elderly patients with dementia. The procedure was finalised on 2 March 2004.  
5/5 
EMEA 2005 
 
 
 
 
 
 
